Cardiome Pharma Corp. (T:COM)
Business Focus: N/A
May 17, 2018 11:34 am ET
May 17, 2018 11:34 am ET
May 17, 2018 07:00 am ET
May 17, 2018 07:00 am ET
May 15, 2018 04:00 pm ET
Correvio Reports First Quarter 2018 Financial Results
Management to Host Conference Call and Webcast Today, May 15, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
May 15, 2018 08:40 am ET
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
NASDAQ: CRME TSX: COM
May 15, 2018 08:40 am ET
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
NASDAQ: CRME TSX: COM
May 10, 2018 07:00 am ET
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome
May 10, 2018 07:00 am ET
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
Shareholders Approve Cipher Acquisition of Canadian Business Portfolio of Cardiome
Apr 26, 2018 04:33 pm ET
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
NASDAQ:CRME, TSX:COM
Apr 26, 2018 04:33 pm ET
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
NASDAQ:CRME, TSX:COM
Apr 17, 2018 08:00 am ET
Apr 17, 2018 08:00 am ET
Apr 12, 2018 07:00 am ET
Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018
NASDAQ: CRME TSX: COM
Apr 12, 2018 07:00 am ET
Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018
NASDAQ: CRME TSX: COM
Apr 06, 2018 06:00 pm ET
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
Apr 06, 2018 06:00 pm ET
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
Apr 02, 2018 08:00 am ET
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
NASDAQ: CRME TSX: COM
Apr 02, 2018 08:00 am ET
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
NASDAQ: CRME TSX: COM
Mar 28, 2018 08:00 am ET
Cardiome Announces Recent Insider Purchases
NASDAQ:CRME TSX:COM
Mar 28, 2018 08:00 am ET
Cardiome Announces Recent Insider Purchases
NASDAQ:CRME TSX:COM
Mar 22, 2018 08:00 am ET
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
Approval Decision Expected in Third Quarter 2018
Mar 22, 2018 08:00 am ET
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
Approval Decision Expected in Third Quarter 2018
Mar 20, 2018 07:00 am ET
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of $25.5 Million CAD
Mar 20, 2018 07:00 am ET
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of $25.5 Million CAD
Mar 13, 2018 04:00 pm ET
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
Management to Host Conference Call and Webcast Today, March 13, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
Mar 13, 2018 04:00 pm ET
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
Management to Host Conference Call and Webcast Today, March 13, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
Mar 06, 2018 03:30 pm ET
Mar 06, 2018 03:30 pm ET
Feb 08, 2018 07:00 am ET
Feb 08, 2018 07:00 am ET
Jan 23, 2018 07:00 am ET
Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
Addition of High-Risk STEMI Patients Significantly Expands the Number of Patients in Which Aggrastat Can Be Used
Jan 23, 2018 07:00 am ET
Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
Addition of High-Risk STEMI Patients Significantly Expands the Number of Patients in Which Aggrastat Can Be Used
Jan 10, 2018 07:00 am ET
Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
NASDAQ:CRME TSX:COM
Jan 10, 2018 07:00 am ET
Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
NASDAQ:CRME TSX:COM
Dec 12, 2017 07:00 am ET
Dec 12, 2017 07:00 am ET
Dec 11, 2017 07:00 am ET
Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission
NDA Expected to be Filed and Accepted by the End of 2018
Dec 11, 2017 07:00 am ET
Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission
NDA Expected to be Filed and Accepted by the End of 2018
Dec 11, 2017 05:00 am ET
Dec 11, 2017 05:00 am ET
Nov 20, 2017 08:00 am ET
Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
NASDAQ: CRME TSX: COM
Nov 20, 2017 08:00 am ET
Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
NASDAQ: CRME TSX: COM
Nov 14, 2017 04:01 pm ET
Cardiome Reports Third Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
Nov 14, 2017 04:01 pm ET
Cardiome Reports Third Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
Nov 07, 2017 08:00 am ET
Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14
NASDAQ: CRME TSX: COM
Nov 07, 2017 08:00 am ET
Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14
NASDAQ: CRME TSX: COM
Nov 02, 2017 09:00 am ET
Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®
– Brinavess® Launched This Week in South Africa; New Distribution Agreement Signed for Pakistan –
Nov 02, 2017 09:00 am ET
Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®
– Brinavess® Launched This Week in South Africa; New Distribution Agreement Signed for Pakistan –
Oct 30, 2017 09:00 am ET
Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies
Marketing and Promotion of Xydalba Has Now Commenced in Six European Countries
Oct 30, 2017 09:00 am ET
Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies
Marketing and Promotion of Xydalba Has Now Commenced in Six European Countries
Sep 12, 2017 08:00 am ET
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel
VANCOUVER, Sept. 12, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera®/Mabelio®. Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. Cardiome will provide Basilea with an upfront payment and additional milestone payments based upon achievement of certain commercial and regulatory milestones. As a result of the agreement, Cardiome will be responsible for the registrat
Sep 12, 2017 08:00 am ET
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel
VANCOUVER, Sept. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera®/Mabelio®. Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. Cardiome will provide Basilea with an upfront payment and additional milestone payments based upon achievement of certain commercial and regulatory milestones. As a result of the agreement, Cardiome will be responsible for the re
Sep 05, 2017 09:00 am ET
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
NASDAQ: CRME TSX: COM
Sep 05, 2017 09:00 am ET
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
NASDAQ: CRME TSX: COM
Aug 30, 2017 09:00 am ET
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®
Results Support the Clinical Utility of BRINAVESS as a Treatment Alternative to Electrical Cardioversion in Patients with Recent Onset Atrial Fibrillation
Aug 30, 2017 09:00 am ET
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®
Results Support the Clinical Utility of BRINAVESS as a Treatment Alternative to Electrical Cardioversion in Patients with Recent Onset Atrial Fibrillation
Aug 21, 2017 09:00 am ET
Cardiome Provides U.S. Regulatory Update For BRINAVESS
NASDAQ:CRME TSX:COM
Aug 21, 2017 09:00 am ET
Cardiome Provides U.S. Regulatory Update For BRINAVESS
NASDAQ:CRME TSX:COM
Aug 08, 2017 05:00 pm ET
Cardiome Reports Second Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
Aug 08, 2017 05:00 pm ET
Cardiome Reports Second Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
Aug 01, 2017 09:00 am ET
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8
NASDAQ: CRME TSX: COM
Aug 01, 2017 09:00 am ET
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8
NASDAQ: CRME TSX: COM
Jul 17, 2017 09:00 am ET
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
NASDAQ: CRME TSX: COM
Jul 17, 2017 09:00 am ET
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
NASDAQ: CRME TSX: COM
Jul 03, 2017 09:00 am ET
Jul 03, 2017 09:00 am ET
Jun 23, 2017 09:00 am ET
Cardiome Pharma Corp. Announces Voting Results
NASDAQ:CRME TSX:COM
Jun 23, 2017 09:00 am ET
Cardiome Pharma Corp. Announces Voting Results
NASDAQ:CRME TSX:COM
Jun 21, 2017 09:00 am ET
Jun 21, 2017 09:00 am ET
Jun 12, 2017 08:30 am ET
Jun 12, 2017 08:30 am ET
May 16, 2017 09:00 am ET
Cardiome Reports Changes To Senior Management Team
NASDAQ: CRME TSX: COM
May 16, 2017 09:00 am ET
Cardiome Reports Changes To Senior Management Team
NASDAQ: CRME TSX: COM
May 15, 2017 05:00 pm ET
Cardiome Reports First Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
May 15, 2017 05:00 pm ET
Cardiome Reports First Quarter 2017 Financial Results
NASDAQ: CRME TSX: COM
May 15, 2017 09:00 am ET
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
May 15, 2017 09:00 am ET
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
May 08, 2017 09:00 am ET
Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15
NASDAQ: CRME TSX: COM
May 08, 2017 09:00 am ET
Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15
NASDAQ: CRME TSX: COM
Apr 27, 2017 09:00 am ET
Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference
NASDAQ: CRME TSX: COM
Apr 27, 2017 09:00 am ET
Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference
NASDAQ: CRME TSX: COM
Apr 06, 2017 09:00 am ET
Apr 06, 2017 09:00 am ET
Apr 03, 2017 09:00 am ET
Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review
NASDAQ: CRME TSX: COM
Apr 03, 2017 09:00 am ET
Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review
NASDAQ: CRME TSX: COM
Mar 14, 2017 04:13 pm ET
IIROC Trade Resumption - COM
TORONTO, March 14, 2017 /CNW/ - Trading resumes in:
Mar 14, 2017 04:02 pm ET
Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS
NASDAQ: CRME TSX: COM
Mar 14, 2017 04:02 pm ET
Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS
NASDAQ: CRME TSX: COM
Mar 14, 2017 03:40 pm ET
IIROC Trading Halt - COM
TORONTO, March 14, 2017 /CNW/ - The following issues have been halted by IIROC:
Mar 07, 2017 04:00 pm ET
Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results
NASDAQ: CRME TSX: COM
Mar 07, 2017 04:00 pm ET
Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results
NASDAQ: CRME TSX: COM
Mar 03, 2017 08:00 am ET
Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in France
NASDAQ: CRME TSX: COM
Mar 03, 2017 08:00 am ET
Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in France
NASDAQ: CRME TSX: COM
Feb 27, 2017 08:00 am ET
Feb 27, 2017 08:00 am ET
Dec 20, 2016 08:00 am ET
Cardiome Announces Commercial Launch of XYDALBA™ (dalbavancin) in Germany
NASDAQ: CRME TSX: COM
Dec 20, 2016 08:00 am ET
Cardiome Announces Commercial Launch of XYDALBA™ (dalbavancin) in Germany
NASDAQ: CRME TSX: COM
Dec 08, 2016 11:55 am ET
Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in the UK
NASDAQ: CRME TSX: COM
Dec 08, 2016 11:55 am ET
Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in the UK
NASDAQ: CRME TSX: COM
Nov 29, 2016 08:00 am ET
Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch
NASDAQ: CRME TSX: COM
Nov 29, 2016 08:00 am ET
Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch
NASDAQ: CRME TSX: COM
Nov 07, 2016 08:00 am ET
Cardiome Reports Third Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast on Monday, November 7, 2016 at 4:00pm Eastern (1:00pm Pacific)
Nov 07, 2016 08:00 am ET
Cardiome Reports Third Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast on Monday, November 7, 2016 at 4:00pm Eastern (1:00pm Pacific)
Nov 01, 2016 09:00 am ET
Cardiome to Reschedule Release of Third Quarter 2016 Financial Results
NASDAQ: CRME TSX: COM
Nov 01, 2016 09:00 am ET
Cardiome to Reschedule Release of Third Quarter 2016 Financial Results
NASDAQ: CRME TSX: COM
Oct 28, 2016 09:00 am ET
Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7
NASDAQ: CRME TSX: COM
Oct 28, 2016 09:00 am ET
Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7
NASDAQ: CRME TSX: COM
Oct 14, 2016 09:00 am ET
Cardiome Announces Initiation of Commercial Operations in Canada, Eh
NASDAQ: CRME TSX: COM
Oct 14, 2016 09:00 am ET
Cardiome Announces Initiation of Commercial Operations in Canada, Eh
NASDAQ: CRME TSX: COM
Aug 16, 2016 09:00 am ET
Cardiome Announces Recent Insider Purchases
NASDAQ: CRME TSX: COM
Aug 16, 2016 09:00 am ET
Cardiome Announces Recent Insider Purchases
NASDAQ: CRME TSX: COM
Aug 09, 2016 05:00 pm ET
Cardiome Announces XYDALBA™ Single Dose Infusion Approval by European Medicines Agency
NASDAQ: CRME TSX: COM
Aug 09, 2016 05:00 pm ET
Cardiome Announces XYDALBA™ Single Dose Infusion Approval by European Medicines Agency
NASDAQ: CRME TSX: COM
Aug 09, 2016 05:00 pm ET
Cardiome Reports Second Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast today, August 9, 2016 at 4:30pm Eastern (1:30pm Pacific)
Aug 09, 2016 05:00 pm ET
Cardiome Reports Second Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast today, August 9, 2016 at 4:30pm Eastern (1:30pm Pacific)
Aug 08, 2016 09:00 am ET
Cardiome Announces the Addition of Two Key Members to its Management Team
NASDAQ: CRME TSX: COM
Aug 08, 2016 09:00 am ET
Cardiome Announces the Addition of Two Key Members to its Management Team
NASDAQ: CRME TSX: COM
Aug 03, 2016 05:30 pm ET
Cardiome to Hold Second Quarter 2016 Financial Results Conference Call on August 9
NASDAQ: CRME TSX: COM
Aug 03, 2016 05:30 pm ET
Cardiome to Hold Second Quarter 2016 Financial Results Conference Call on August 9
NASDAQ: CRME TSX: COM
Jul 29, 2016 10:53 am ET
Cardiome Closes Public Offering of 11,500,000 Common Shares
NASDAQ: CRME TSX: COM
Jul 29, 2016 10:53 am ET
Cardiome Closes Public Offering of 11,500,000 Common Shares
NASDAQ: CRME TSX: COM
Jul 26, 2016 09:38 am ET
Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares
NASDAQ: CRME TSX: COM
Jul 26, 2016 09:38 am ET
Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares
NASDAQ: CRME TSX: COM
Jul 25, 2016 05:01 pm ET
Cardiome Announces Proposed Public Offering of Common Shares
NASDAQ: CRME TSX: COM
Jul 25, 2016 05:01 pm ET
Cardiome Announces Proposed Public Offering of Common Shares
NASDAQ: CRME TSX: COM
Jul 14, 2016 09:00 am ET
ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy
NASDAQ: CRME TSX: COM
Jul 14, 2016 09:00 am ET
ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy
NASDAQ: CRME TSX: COM
Jun 24, 2016 09:00 am ET
Cardiome Pharma Corp. Announces Voting Results
NASDAQ: CRME TSX: COM
Jun 24, 2016 09:00 am ET
Cardiome Pharma Corp. Announces Voting Results
NASDAQ: CRME TSX: COM
Jun 14, 2016 09:00 am ET
Cardiome Announces Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
Jun 14, 2016 09:00 am ET
Cardiome Announces Term Loan Agreement with CRG-Managed Funds
NASDAQ: CRME TSX: COM
May 13, 2016 08:00 am ET
Cardiome Reports First Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast today, May 13, 2016 at 8:00am Eastern (5:00am Pacific)
May 13, 2016 08:00 am ET
Cardiome Reports First Quarter 2016 Financial Results
Cardiome to conduct conference call and webcast today, May 13, 2016 at 8:00am Eastern (5:00am Pacific)
May 12, 2016 09:00 am ET
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
NASDAQ: CRME TSX: COM
May 12, 2016 09:00 am ET
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
NASDAQ: CRME TSX: COM
May 11, 2016 09:00 am ET
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
NASDAQ: CRME TSX: COM
May 11, 2016 09:00 am ET
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study
NASDAQ: CRME TSX: COM
May 11, 2016 09:00 am ET
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13
NASDAQ: CRME TSX: COM
May 11, 2016 09:00 am ET
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13
NASDAQ: CRME TSX: COM
May 06, 2016 09:12 am ET
IIROC Trade Resumption - COM
TORONTO, May 6, 2016 /CNW/ - Trading resumes in:
May 05, 2016 05:41 pm ET
IIROC Trading Halt - COM
TORONTO, May 5, 2016 /CNW/ - The following issues have been halted by IIROC:
May 05, 2016 05:15 pm ET
May 05, 2016 05:15 pm ET
Apr 28, 2016 09:00 am ET
Cardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference
NASDAQ: CRME TSX: COM
Apr 28, 2016 09:00 am ET
Cardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference
NASDAQ: CRME TSX: COM
Mar 31, 2016 09:00 am ET
Mar 31, 2016 09:00 am ET
Mar 10, 2016 07:00 am ET
Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results
Cardiome to conduct conference call and webcast today, March 10, 2016 at 8:00 a.m. Eastern (5:00 a.m. Pacific)
Mar 10, 2016 07:00 am ET
Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results
Cardiome to conduct conference call and webcast today, March 10, 2016 at 8:00 a.m. Eastern (5:00 a.m. Pacific)
Mar 07, 2016 05:53 pm ET
Cardiome Announces Filing of Prospectus Supplements
NASDAQ: CRME TSX: COM
Mar 07, 2016 05:53 pm ET
Cardiome Announces Filing of Prospectus Supplements
NASDAQ: CRME TSX: COM
Mar 04, 2016 03:24 pm ET
Cardiome To Hold Fourth Quarter And Full Year 2015 Financial Results Conference Call On March 10
VANCOUVER, March 4, 2016 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2015 on the morning of Thursday, March 10, 2016. Cardiome will hold a conference call and webcast at 8:00 a.m. Eastern (5:00 a.m. Pacific) on that day to discuss the results.
Mar 04, 2016 03:24 pm ET
Cardiome To Hold Fourth Quarter And Full Year 2015 Financial Results Conference Call On March 10
VANCOUVER, March 4, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2015 on the morning of Thursday, March 10, 2016. Cardiome will hold a conference call and webcast at 8:00 a.m. Eastern (5:00 a.m. Pacific) on that day to discuss the results.
Feb 19, 2016 04:46 pm ET
Cardiome announces filing of shelf prospectus and registration statement
NASDAQ: CRME TSX: COM
Feb 19, 2016 04:46 pm ET
Cardiome announces filing of shelf prospectus and registration statement
NASDAQ: CRME TSX: COM
Feb 10, 2016 08:00 am ET
Feb 10, 2016 08:00 am ET
Jan 27, 2016 08:00 am ET
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
NASDAQ: CRME TSX: COM
Jan 27, 2016 08:00 am ET
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA
NASDAQ: CRME TSX: COM
Jan 21, 2016 08:00 am ET
Cardiome Announces the Launch of ESMOCARD LYO in Belgium
NASDAQ: CRME TSX: COM
Jan 21, 2016 08:00 am ET
Cardiome Announces the Launch of ESMOCARD LYO in Belgium
NASDAQ: CRME TSX: COM
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.